Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,824 across all filing types
Latest filing 2025-01-13 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is titled as a "股票交易异常波动公告" which translates to "Stock Trading Abnormal Fluctuation Announcement." It discusses the abnormal price fluctuations of the company's stock over three trading days, the company's self-inspection results, confirmation from controlling shareholders, and risk warnings to investors. It explicitly states that no undisclosed material information exists and references other announcements for detailed financial results and clarifications. The document is relatively short (1786 characters) and serves as an announcement regarding stock price volatility rather than a financial report or detailed filing. It does not contain financial statements, audit information, or management discussions. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-01-13 Chinese
哈药集团股份有限公司2024年年度业绩预增公告
Earnings Release Classification · 95% confidence The document is titled as a 2024 annual performance forecast announcement by 哈药集团股份有限公司. It provides estimated net profit figures for the full year 2024, comparing them to the previous year, and explains reasons for the expected profit increase. It explicitly states that the forecast is unaudited and that the final accurate financial data will be disclosed in the formal 2024 annual report. The document is short (1268 characters) and serves as a preliminary earnings forecast rather than a full financial report. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only, not the full annual report (10-K). FY 2024
2025-01-10 Chinese
哈药集团股份有限公司关于媒体报道的澄清公告
Regulatory Filings Classification · 95% confidence The document is a clarification announcement from 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.) addressing misleading media reports about a product and regulatory actions by the National Medical Products Administration. It contains no financial data, no report or financial statements, and is not a meeting material or voting result. It is a regulatory announcement clarifying facts to investors and the public. The document length is short (1066 characters), and it is not a report publication announcement but a regulatory disclosure. Therefore, it fits best under Regulatory Filings (RNS).
2025-01-10 Chinese
哈药集团有限公司关于哈药集团股份有限公司股票交易异常波动询证函的回复
Regulatory Filings
2025-01-06 Chinese
哈药集团股份有限公司股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is titled as a "股票交易异常波动公告" which translates to "Stock Trading Abnormal Fluctuation Announcement." It discusses the abnormal price fluctuations of the company's stock over two consecutive trading days, confirms that no undisclosed material information exists, and warns investors about market risks. There is no financial data, no detailed report, or management discussion. The document is an official announcement regarding stock price abnormality and related disclosures, fitting the category of Regulatory Filings (RNS) as it is a regulatory announcement about stock trading behavior and compliance with exchange rules, not a financial report or other specific filing type.
2025-01-06 Chinese
哈药集团股份有限公司关于转回资产减值准备公告
Capital/Financing Update Classification · 90% confidence The document is an announcement from 哈药集团股份有限公司 regarding the reversal of asset impairment provisions. It details the background of the impairment, repayments received, and the financial impact on the company's profit. The document is relatively short (881 characters) and focuses on a specific financial event rather than providing a comprehensive financial report or audit. It does not contain full financial statements or detailed financial analysis typical of Annual Reports (10-K) or Interim Reports (IR). It is also not a certification, call transcript, or management discussion. The content fits best with a Capital/Financing Update (CAP) as it relates to changes in asset valuation and financial adjustments impacting the company's capital and profit. Therefore, the appropriate classification is CAP with high confidence.
2024-12-30 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.